New Advance in PARP Inhibitors as Anticancer Agents
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Bioorganic Chemistry".
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 339
Special Issue Editors
Interests: PARP inhibitor; cancer; breast cancer; mitochondria
Interests: natural products; enzyme inhibition; cytotoxicity; antitumor active compounds; triterpenes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
PARP enzyme family members have attracted increasing interest in the last decade among both scientists in the field and clinicians due to the success of PARP inhibitors in cancer therapy. PARP inhibitors were first approved by the FDA for the treatment of BRCA1/2 mutated breast and ovarian cancers, but in recent years, they have also been used in advanced prostate and pancreas cancers.
Several ongoing studies are focusing on the identification of new biomarkers and the clarification of changed molecular mechanisms in the pathophysiology of different cancer types. The results of these investigations give the possibility for the development of novel, more effective, and personalized targeted therapies.
This Special Issue “New Advances in PARP Inhibitors as Anticancer Agents” of Molecules aims at providing an updated overview of basic and preclinical knowledge on the pathophysiology and molecular profiling of different cancer types as well as on the development of innovative targeted therapeutic approaches while taking into account promises and pitfalls.
Dr. Krisztina Kovács
Prof. Dr. René Csuk
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PARP inhibitor
- cancer therapy
- resistance
- cytotoxicity
- enzyme inhibition
